Browsing Tag
Recordati
2 posts
Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market
Angelini Pharma will pay $4.1 billion for Catalyst Pharmaceuticals at $31.50 a share, but CPRX closed at $31.10. The premium sits in the strategy, not the price.
CVC Capital Partners leads consortium in €3.03bn acquisition of Recordati
In a landmark deal valued at approximately €3.03 billion, a consortium led by CVC Capital Partners through its…